SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
Filed by the registrant [ X ]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[ ] Preliminary proxy statement.
[X] Definitive proxy statement.
[ ] Definitive additional materials.
[ ] Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12. [ ]
Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)).
UCI MEDICAL AFFILIATES, INC.
(Name of Registrant as Specified in Its Charter)
Payment of filing fee (check the appropriate box):
[ X ] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction
applies:
(3) Per unit price or other underlying value of transaction
computed pursuant to Exchange Act Rule 0-11 (set forth the
amount on which the filing fee is calculated and state how it
was determined):
(4) Proposed maximum aggregate value of
transaction:
(5) Total fee
paid:
[ ] Fee paid previously with preliminary
materials.
- ----------
[ ] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration
statement number, or the form or schedule and the date of its filing.
(1) Amount Previously
Paid:
(2) Form, Schedule or Registration Statement
No.:
(3) Filing
Party:
(4) Date
Filed:
UCI MEDICAL AFFILIATES, INC.
1901 Main Street, Suite 1200
Columbia, South Carolina 29201
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To be held on Thursday, March 23, 2000
TO THE STOCKHOLDERS OF UCI MEDICAL AFFILIATES, INC.:
The Annual Meeting of Stockholders of UCI Medical Affiliates, Inc., a
Delaware corporation (the "Company"), will be held on Thursday, March 23, 2000
at 10:00 a.m., local time, at the Adam's Mark Hotel, 1200 Hampton Street,
Columbia, South Carolina for the following purposes:
1. To approve the election of two members of the Board of Directors, each
to hold office for a term expiring at the third annual meeting of
stockholders after the date of their election.
2. To ratify the appointment of PricewaterhouseCoopers LLP as the firm of
independent auditors to audit the consolidated financial statements of
the Company and its subsidiaries for the fiscal year ended September
30, 2000.
3. To transact such other business as may properly come before the Annual
Meeting or any adjournment or postponement of the Annual Meeting.
The foregoing items of business are more fully described in the Proxy
Statement accompanying this Notice. Only stockholders of record of the Company's
common stock at the close of business on January 28, 2000 are entitled to notice
of, and will be entitled to vote at, the Annual Meeting or any adjournment or
postponement of the Annual Meeting.
BY ORDER OF THE BOARD OF DIRECTORS
M. F. McFarland, III, M.D.
Chairman of the Board
and Chief Executive Officer
January 28, 2000
To ensure that your shares are represented at the Annual Meeting, we
urge you to complete, date and sign the enclosed form of proxy and mail it
promptly in the postage-paid envelope provided, whether or not you plan to
attend the Annual Meeting in person. Your proxy can be withdrawn by you at any
time before it is voted.
UCI MEDICAL AFFILIATES, INC.
1901 Main Street, Suite 1200
Mail Code 1105
Columbia, South Carolina 29201
PROXY STATEMENT
General
This Proxy Statement is furnished in connection with the solicitation
of proxies by the Board of Directors of UCI Medical Affiliates, Inc. (the
"Company") to be used in voting at the Annual Meeting of Shareholders of the
Company to be held at the Adam's Mark Hotel, 1200 Hampton Street, Columbia,
South Carolina, on Thursday, March 23, 2000, at 10:00 a.m., and at any
adjournment thereof. The purposes of the Annual Meeting are (1) to elect two
directors to the Company's Board of Directors, (2) to ratify the appointment of
PricewaterhouseCoopers LLP as the Company's independent auditors for the fiscal
year ending September 30, 2000; and (3) to transact such other business as may
properly come before the Annual Meeting or any adjournment of the Annual
Meeting. This Proxy Statement and the accompanying form of proxy are being
mailed to stockholders commencing on or about February 2, 2000.
Record Date
Only holders of record of the Company's common stock, par value $0.05
per share (the "Common Stock"), at the close of business on January 28, 2000
(the "Record Date") are entitled to notice of and will be entitled to vote at
the Annual Meeting.
Shares Outstanding and Entitled to Vote
The Common Stock is entitled to one vote per share on each matter that
is presented for stockholder approval at the Annual Meeting. At the close of
business on the Record Date, there were 9,642,958 shares of Common Stock
outstanding and entitled to vote, held of record by approximately 327
stockholders. All of such shares are eligible to be voted on each matter
currently scheduled to come before the Annual Meeting.
Voting and Revocation of Proxies
The form of proxy accompanying this Proxy Statement is solicited on
behalf of the Company's Board of Directors for use at the Annual Meeting. You
are requested to complete, date and sign the accompanying form of proxy and
promptly return it in the accompanying envelope or otherwise mail it to the
Company. All proxies that are properly executed and returned, and that are not
revoked, will be voted at the Annual Meeting in accordance with the instructions
indicated on the proxies. If no instructions are indicated, such proxies will be
voted FOR each of the proposals described in this Proxy Statement, including
election of the director nominees set forth in this Proxy Statement.
The Board of Directors does not presently intend to bring any business
before the Annual Meeting other than the specific proposals referred to in this
Proxy Statement and specified in the notice of the Annual Meeting. So far as is
known to the Board, no other matters are to be brought before the Annual
Meeting. If any other business properly comes before the Annual Meeting,
however, it is intended that proxies, in the form enclosed, will be voted on
such matters in accordance with the judgment of the persons voting such proxies.
Any stockholder of the Company who has signed the proxy referred to in
this Proxy Statement may revoke it at any time before it is exercised at the
Annual Meeting by (i) delivering to the Corporate Secretary of the Company a
written notice, bearing a date later than the proxy, stating that the proxy is
revoked, (ii) signing and so delivering a proxy relating to the same shares and
bearing a later date prior to the vote at the Annual Meeting or (iii) attending
the Annual Meeting and voting in person (although attendance at the Annual
Meeting will not, by itself, revoke a proxy). Whether or not you plan to attend
the Annual Meeting, you are urged to sign and return the enclosed proxy.
Quorum
The quorum required for the transaction of business at the Annual
Meeting is a majority of the issued and outstanding shares of Common Stock on
the Record Date, or 4,821,480 shares. Such shares must be present in person or
represented by proxy at the Annual Meeting. Directions to withhold authority to
vote for directors, abstentions and broker non-votes will be considered shares
present in person or by proxy and entitled to vote and therefore will be counted
for purposes of determining whether there is a quorum at the Annual Meeting. If
a quorum is not present or represented at the Annual Meeting, the chairman of
the meeting or the stockholders holding a majority of the shares of Common Stock
entitled to vote, present in person or represented by proxy, have the power to
adjourn the meeting from time to time, without notice other than an announcement
at the meeting, until a quorum is present or represented. Directors, officers
and employees of the Company may solicit proxies for the reconvened Annual
Meeting in person or by mail, telephone or telegraph. At any such reconvened
Annual Meeting at which a quorum is present or represented, any business may be
transacted that might have been transacted at the meeting as originally
scheduled.
Vote Required
Except for the election of directors, for each matter specified in this
Proxy Statement to be submitted for stockholder approval at the Annual Meeting,
the affirmative vote of a majority of the shares of Common Stock present at the
Annual Meeting in person or by proxy and entitled to vote on such matter is
required for approval. Abstentions will be considered shares present in person
or by proxy and entitled to vote and, therefore, will have the effect of a vote
against such matter. Broker non-votes will be considered shares present but not
entitled to vote and, therefore, will have no effect on the outcome of the vote.
Under the Delaware General Corporation Law, the two director nominees
receiving the greatest number of votes cast (although not necessarily a majority
of the votes cast) in the election of directors at the Annual Meeting will be
elected to the Board of Directors. Accordingly, directions to withhold
authority, abstentions and broker non-votes will have no effect on the outcome
of the vote for directors. The Company's Restated Certificate of Incorporation
does not allow for cumulative voting in the election of directors.
A broker non-vote occurs when a broker or other nominee holding shares
for a beneficial owner votes on one proposal, but does not vote on another
proposal because the broker or other nominee does not have the discretionary
voting power and has not received voting instructions from the beneficial owner.
Solicitation of Proxies and Expenses
The Company will bear the cost of preparing, assembling and mailing
this Proxy Statement and the accompanying form of proxy to stockholders. In
addition to solicitation by mail, the directors, officers and employees of the
Company may solicit proxies from stockholders by telephone, telegram, letter,
facsimile or in person. No compensation will be paid for such solicitations. The
Company may request brokers, custodians, nominees and other record holders to
forward copies of the proxy and other soliciting materials to persons for whom
they hold shares of Common Stock and to request authority for the exercise of
proxies. In such cases, the Company, upon the request of the record holders,
will reimburse such holders for their reasonable expenses.
PROPOSAL ONE
ELECTION OF DIRECTORS
Two directors are to be elected at the Annual Meeting. The Company's
Certificate of Incorporation provides for a classified Board of Directors so
that, as nearly as possible, one-third of the Board is elected at each annual
meeting to serve until the third annual stockholders' meeting after their
election. Pursuant to the authority granted to it under the Company's Bylaws,
the Board has set the size of the Board at seven members with staggered terms
expiring at the forthcoming Annual Meeting and at the next two succeeding annual
meetings of stockholders. Harold H. Adams, Jr. and Thomas G. Faulds have been
nominated by the Board of Directors for election as directors at the forthcoming
Annual Meeting for terms expiring at the third annual meeting of stockholders
after the date of their election. Mr. Adams' and Mr. Faulds' terms as directors
expire at the forthcoming Annual Meeting. See "Management."
The persons named in the accompanying proxy have been designated by the
Board and, unless authority is specifically withheld, they intend to vote for
the election of the nominees listed above. A stockholder executing the enclosed
proxy may vote for the nominees or may withhold such vote from the nominees. In
each case where the stockholder has appropriately specified how the proxy is to
be voted, it will be voted in accordance with such stockholder's specifications.
Although it is not contemplated that the nominees will become unable to serve
prior to the Annual Meeting, the persons named on the enclosed proxy will have
the authority to vote for the election of another person in accordance with
their best judgment.
THE PERSONS NAMED IN THE FORM OF PROXY WILL VOTE THE PROXY AS
SPECIFIED. IF NO SPECIFICATION IS MADE, THE PROXY WILL BE VOTED "FOR" THE
ELECTION OF THE NOMINEES LISTED ABOVE.
PROPOSAL TWO
RATIFICATION OF APPOINTMENT OF AUDITORS
The Board, adopting the recommendation of the Audit Committee of the
Board of Directors (the "Audit Committee"), has appointed the certified public
accounting firm of PricewaterhouseCoopers LLP as the Company's independent
auditors for the fiscal year ended September 30, 2000, subject to ratification
by the stockholders at the Annual Meeting. Representatives of
PricewaterhouseCoopers LLP are expected to be present at the Annual Meeting and
will be available to respond to questions and may make a statement if such
representatives so desire.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THIS PROPOSAL. THE
PERSONS NAMED IN THE FORM OF PROXY WILL VOTE THE PROXY AS SPECIFIED. IF NO
SPECIFICATION IS MADE, THE PROXY WILL BE VOTED "FOR" THE RATIFICATION OF THE
COMPANY'S INDEPENDENT AUDITORS.
OTHER MATTERS
The Board of Directors knows of no other matters which are likely to be
brought before the Annual Meeting. If any matters are brought before the Annual
Meeting, the proxy agents named in the enclosed proxy will vote on such matters
in accordance with their best judgment.
MANAGEMENT
Directors
The following sets forth certain information concerning the persons
nominated for election as directors and the current directors whose terms will
continue beyond the Annual Meeting. As used in this proxy statement, the term
UCI-SC refers to UCI Medical Affiliates of South Carolina, Inc., a wholly-owned
subsidiary of the Company; the term DC-SC refers to Doctor's Care P.A., a
professional corporation affiliated with the Company and UCI-SC; and the term
UCI-GA refers to UCI Medical Affiliates of Georgia, Inc., a wholly-owned
subsidiary of the Company.
Nominees for Election as Directors at the Annual Meeting
Harold H. Adams, Jr., 53, has served as a director of the Company since
June 1994 and as President and owner of Adams and Associates, International,
Adams and Associates, and Southern Insurance Managers since June 1992. He served
as President of Adams Eaddy and Associates, an independent insurance agency,
from 1980 to 1992. Mr. Adams has been awarded the Chartered Property Casualty
Underwriter designation and is currently a member of the President's Board of
Visitors of Charleston Southern University in Charleston, South Carolina. He has
received numerous professional awards as the result of over 26 years of
involvement in the insurance industry and is a member of many professional and
civic organizations.
Thomas G. Faulds, 59, has served as a director of the Company since
August 1996 and as President and Chief Operating Officer, Blue Cross Blue Shield
Division, Blue Cross Blue Shield of South Carolina ("BCBS") since October 1991.
Mr. Faulds has been with BCBS since March 1972 where he has served in key senior
management positions in government programs, information systems and operations.
Directors Whose Terms Extend Beyond the Date of the Annual Meeting
A. Wayne Johnson, 49, has served as Chairman and Chief Executive
Officer of MainStreet Healthcare Corporation ("MHC") from its inception in
February 1996. In addition to Mr. Johnson's MainStreet responsibilities,
effective December 8, 1999, he assumed the role of Executive Vice President of
Providan Financial, a San Francisco-based financial services company. Mr.
Johnson has 24 years of entrepreneurial and business operations experience in
the field of financial services and corporate development. Prior to co-founding
MHC in February 1996, Mr. Johnson had served since 1991 as President of one of
the major operating subsidiaries of First Data Corporation and Chief Marketing
Officer and strategic planner for First Data Card Services Group, a subsidiary
of First Data Corporation. Mr. Johnson was the founder of both Integratec, a
collection company, and QualiServ, a credit card outsourcing service company.
Mr. Johnson was initially elected as a director at the annual meeting of
stockholders in 1999.
Ashby M. Jordan, M.D., 61, has served as a director of the Company since
August 1996 and as Vice President of Medical Affairs of BCBS since December
1986. Prior to joining BCBS, Dr. Jordan was the Vice President of Medical
Affairs for CIGNA HealthPlan of South Florida, Inc. Dr. Jordan is Board
Certified by the American Board of Pediatrics. Dr. Jordan was most recently
reelected as a director at the annual meeting of stockholders in 1999.
John M. Little, Jr., M.D., 50, has served as a director of the Company
since August 11, 1998 and as Chief Medical Officer of Companion HealthCare
Corporation ("CHC"), a wholly-owned subsidiary of BCBS, since 1996.
Additionally, he has served since 1994 as Medical Director of Managed Care
Services of CHC, as Chairman of the Quality Assurance Committee and the Pharmacy
and Therapeutics Committee of CHC and as a Co-Chair of the Managed Care
Oversight Committee of CHC. Prior to joining CHC in 1994, Dr. Little served as
Assistant Chairman for Academic Affairs, Department of Family Practice,
Carolinas Medical Center, Charlotte, North Carolina from 1992 to 1994. Dr.
Little was most recently reelected as a director at the annual meeting of
stockholders in 1999.
M.F. McFarland, III, M.D., 52, has served as Chairman of the Board,
President and Chief Executive Officer of the Company since January 1987 and as a
director of the Company since September 1984. From September 1984 until January
1987, he served as Vice President of the Company. He has served as President and
as the sole director of UCI-SC and DC-SC for over five years and of UCI-GA since
its organization in February 1998. He served as Associate Professional Director
of the Emergency Department of Richland Memorial Hospital in Columbia, South
Carolina from 1978 to 1981 and was President of the South Carolina Chapter of
the American College of Emergency Physicians in 1979. Dr. McFarland is currently
a member of the Columbia Medical Society, the South Carolina Medical Association
and the American Medical Association. Dr. McFarland was most recently reelected
as a director at the annual meeting of stockholders in 1997.
Charles M. Potok, 51, has served as a director of the Company since
September 1995 and as Executive Vice President and Chief Operating Officer of
Companion Property and Casualty Company ("CP&C"), a wholly-owned subsidiary of
BCBS, since March 1984. Mr. Potok is an Associate of the Casualty Actuarial
Society and a member of the American Academy of Actuaries. Prior to joining
CP&C, Mr. Potok served as Chief Property and Casualty Actuary and Director of
the Property and Casualty Division of the South Carolina Department of
Insurance. Mr. Potok was most recently reelected as a director at the annual
meeting of stockholders in 1997.
Executive Officers
The following sets forth certain information concerning the persons who
currently serve as executive officers of the Company who do not also serve on
the Board of Directors.
Jerry F. Wells, Jr., 38, has served as Chief Financial Officer and
Executive Vice President of Finance of the Company since he joined the Company
in February 1995 and as Corporate Secretary of the Company since December 1996.
He has served as Executive Vice President of Finance, Chief Financial Officer
and Corporate Secretary of UCI-SC since December 1996, and of UCI-GA since its
organization in February 1998, and as Corporate Secretary of DC-SC since
December 1996. Prior to joining the Company, he served as a Senior Manager and
consultant for PricewaterhouseCoopers LLP from 1985 until February 1995. Mr.
Wells is a certified public accountant and is a member of the American Institute
of Certified Public Accountants, the South Carolina Association of Certified
Public Accountants and the North Carolina CPA Association.
D. Michael Stout, M.D., 55, has served as Executive Vice President of
Medical Affairs of the Company and DC-SC since 1985. He is Board Certified in
Emergency Medicine and is a member of the American College of Emergency
Physicians, the Columbia Medical Society and the American College of Physician
Executives.
Board of Directors and Board Committees
Board of Directors
The Board of Directors met or acted by written consent a total of five
times during the Company's fiscal year ended September 30, 1999. No director
attended fewer than 75 percent of the total of such Board meetings and the
meetings of the committees upon which the director served. Among the standing
committees established by the Board of Directors are a Compensation Committee,
an Audit Committee, and a Revenue Enhancement Committee. The Board of Directors
has not established a nominating committee for recommending to stockholders
candidates for positions on the Board of Directors. Such functions are currently
performed by the Board of Directors acting as a whole. Currently, seven
directors serve on the Board of Directors.
Audit Committee
The Audit Committee consists of Mr. Adams and Dr. Jordan. This
committee recommends to the Board of Directors the engagement of the independent
auditors for the Company, determines the scope of the auditing of the books and
accounts of the Company, reviews the reports submitted by the auditors, examines
procedures employed in connection with the Company's internal control structure,
reviews and approves the terms of acquisitions between the Company and any
related party entities, undertakes certain other activities related to the
fiscal affairs of the Company and makes recommendations to the Board of
Directors as may be appropriate. This committee met one time during the
Company's fiscal year ended September 30, 1999.
Compensation Committee
The Compensation Committee consists of Messrs Adams and Potok. This
committee monitors the Company's executive compensation plan, practice and
policies, including all salaries, bonus awards and fringe benefits, and makes
recommendations to the Board of Directors with respect to changes in existing
executive compensation plans and the formation and adoption of new executive
compensation plans. This committee met one time during the Company's fiscal year
ended September 30, 1999.
Revenue Enhancement Committee
The Revenue Enhancement Committee consists of Messrs. Adams, Faulds and
Potok. This committee monitors the Company's ancillary and complementary
services, and makes recommendations to the Board of Directors with respect to
changes in such existing services. This committee did not meet during the
Company's fiscal year ended September 30, 1999.
Executive Compensation
The following table sets forth the total compensation earned during the
fiscal year ended September 30, 1999 and during each of the two prior fiscal
years by the President and Chief Executive Officer of the Company and the
executive officers of the Company whose annual compensation from the Company
exceeded $100,000 for all services provided to the Company. No other executive
officer of the Company earned compensation in excess of $100,000 for services
provided to the Company in any of the three fiscal years reflected in the table.
SUMMARY COMPENSATION TABLE
Long Term
Compensation
Annual Compensation Awards
Securities
Fiscal Underlying All Other
Name and Principal Position Year Salary (1) Bonus(1) Compensation (2)
Options
M.F. McFarland, III, M.D. 1999 $ 325,000 (3) $ 200,000 -0- 5,561
Chairman, President and 1998 315,000 (3) -0- -0- 8,983
Chief Executive Officer 1997 315,000 (3) -0- 141,675 7,968
D. Michael Stout, M.D. 1999 $ 210,000 (4) $ 42,000 -0- -0-
Executive Vice President of 1998 210,000 (4) -0- -0- -0-
Medical Affairs 1997 210,000 (4) -0- 79,825 -0-
Jerry F. Wells, Jr. 1999 $ 99,640 $ 17,260 -0- $ -0-
Executive Vice President of 1998 96,769 -0- -0- -0-
Finance, Chief 1997 92,161 -0- 106,550 -0-
Financial Officer
(1) Amounts included under the heading "Salary" and "Bonus" include
compensation from both UCI-SC and DC-SC. The remuneration described in
the table above does not include the cost to the Company of benefits
furnished to certain officers that were extended in connection with the
conduct of the Company's business. The amount of such benefits accrued
for each of the named executives in each of the years reflected in the
table did not exceed 10% of the total annual salary and bonus reported
for such executive in such year.
(2) Amounts included under the heading "All Other Compensation" are
comprised of premiums for long term disability and life insurance
provided by the Company for the benefit of Dr. McFarland.
(3) For services performed by Dr. McFarland for UCI-SC, a wholly-owned
subsidiary of the Company, Dr. McFarland received an annual salary of
$157,500 during each of the fiscal years ended September 30, 1999, 1998
and 1997. For services performed by Dr. McFarland for DC-SC, an
affiliated professional association wholly owned by Dr. McFarland that
contracts with UCI-SC to provide all medical services at the Company's
medical facilities, Dr. McFarland received an annual salary of
$167,500, $157,500 and $157,500 for the fiscal years ended September
30, 1999, 1998 and 1997, respectively.
(4) For services performed by Dr. Stout for UCI-SC, Dr. Stout received an
annual salary of $50,000 in each of the fiscal years ended September
30, 1999, 1998, and1997. For services performed by Dr. Stout for DC-SC,
Dr. Stout received an annual salary of $160,000 in each of the fiscal
years ended September 30, 1999, 1998 and 1997.
Fiscal Year-End Option Values
The following table sets forth certain information with respect to
unexercised options to purchase Common Stock held at September 30, 1999. None of
the named executive officers exercised any options during the fiscal year ended
September 30, 1999.
1999 FISCAL YEAR-END
OPTION VALUES
Number of Securities Underlying Value of Unexercised
Unexercised Options at In-the-Money
Fiscal Year End Options at Fiscal Year End
Name Exercisable Unexercisable Exercisable Unexercisable
M.F. McFarland, III, M.D. 159,450 47,225 $ $
Chairman, President and -0- -0-
Chief Executive Officer
D. Michael Stout, M.D. 83,216 26,609 -0- -0-
Executive Vice President of
Medical Affairs
Jerry F. Wells, Jr. 106,550 28,275 -0- -0-
Executive Vice President of
Finance, Chief
Financial Officer
Director Compensation
Non-employee directors are paid a fee of $500 for attendance at each
meeting of the Board of Directors. Non-employee directors of the Company are
reimbursed by the Company for all out-of-pocket expenses reasonably incurred by
them in the discharge of their duties as directors, including out-of-pocket
expenses incurred in attending meetings of the Board of Directors.
During the fiscal year ended September 30, 1996, the Company adopted a
Non-Employee Director Stock Option Plan (the "1996 Non-Employee Plan"). The 1996
Non-Employee Plan provided for the granting of options to two non-employee
directors for the purchase of 10,000 shares of Common Stock at the fair market
value as of the date of grant. Under this plan, 5,000 options were issued to
Harold H. Adams, Jr. and 5,000 options were issued to Russell J. Froneberger.
These options are exercisable during the period commencing on March 20, 1999 and
ending on March 20, 2006. At September 30, 1999, there were stock options
outstanding under the 1996 Non-Employee Plan for 10,000 shares, all of which
were exercisable.
During the fiscal year ended September 30, 1997, the Company adopted a
Non-Employee Director Stock Option Plan (the "1997 Non-Employee Plan"). The 1997
Non-Employee Plan provided for the granting of options to four non-employee
directors for the purchase of 20,000 shares of Common Stock at the fair market
value as of the date of grant. Under this plan, 5,000 options were issued each
to Thomas G. Faulds, Ashby M. Jordan, M.D., and Charles M. Potok. These options
are exercisable during the period commencing on March 28, 2000 and ending on
March 28, 2007. At September 30, 1999, there were stock options outstanding
under the 1997 Non-Employee Plan for 15,000 shares, none of which were
exercisable.
Employment Contracts
Effective August 19, 1999, Dr. McFarland entered into a five-year
contract with UCI-SC that provides for annual compensation of $157,500, the use
of one automobile and an incentive bonus payable at the end of the fiscal year,
subject to the determination of the Board of Directors and based upon net income
and gross revenue of the Company for the same year. Also, effective August 19,
1999, Dr. McFarland entered into a five-year contract with DC-SC that provides
for annual compensation of $167,500, plus a three percent annual cost of living
increase.
Effective November 1, 1995, Dr. Stout entered into a five-year contract
with UCI-SC that provides for annual compensation of $50,000. Also, effective
November 1, 1995, Dr. Stout entered into a five-year contract with DC-SC that
provides for annual compensation of $160,000.
Compensation Committee Interlocks and Insider Participation
During the fiscal year ended September 30, 1999, matters of executive
compensation were decided by the Compensation Committee of the Board of
Directors. The Compensation Committee is currently composed of Messrs. Adams and
Potok.
Compensation Committee Report on Executive Compensation
The compensation of the Company's executive officers is generally
determined by the Compensation Committee of the Board of Directors. The
following report with respect to certain compensation paid or awarded to the
Company's executive officers during the fiscal year ended September 30, 1999 is
furnished by the directors who comprise the Compensation Committee.
General Policies. The Company's compensation program is intended to
enable the Company to attract, motivate, reward and retain the management talent
to achieve corporate objectives, and thereby increase shareholder value. It is
the Company's policy to provide incentives to senior management to achieve both
short-term and long-term objectives. To attain these objectives, the Company's
executive compensation program is composed of a base salary and bonus, which is
generally established for the executive officers in an employment agreement.
Base Salary. Base salaries for each of Dr. McFarland, Dr. Stout and Mr.
Wells were determined by a subjective assessment of the executive officer's
performance, in light of the officer's responsibilities and position with the
Company and the Company's performance during prior periods. In evaluating
overall Company performance, the primary focus is upon not only the Company's
financial performance, but also on the personal performance of the executives in
areas such as quality assurance and personal development.
Incentive Compensation. Incentive compensation for each of Dr.
McFarland and Dr. Stout is established in his employment agreement and is most
influenced by the Company's profitability. It is completely "at risk" depending
upon the Company's performance. Incentive compensation is reviewed periodically
and from time to time by the Compensation Committee and adjusted accordingly.
Chief Executive Officer Compensation. Dr. McFarland is one of the original
founders of the Company and has devoted his career to the Company since its
inception in 1984. The Compensation Committee believes that Dr. McFarland's
drive, dedication, commitment and knowledge have been vitally important to the
successful and ongoing growth of the Company. Dr. McFarland's overall
compensation for the fiscal year ended September 30, 1999 consisted of base
salary and bonus. In determining Dr. McFarland's compensation, the Compensation
Committee evaluated Dr. McFarland's personal performance, the performance of the
Company and Dr. McFarland's long-term commitment to the success of and ownership
position in the Company.
Stock Options. Executive compensation includes the grant of stock
options in order to more closely align the interests of the executive with the
long-term interests of the shareholders.
Report of Compensation Committee: Harold H. Adams, Jr.
Thomas G. Faulds
Performance Graph
The following graph compares cumulative total shareholder return of the
Common Stock over a five-year period with The Nasdaq Stock Market (US) Index and
with a Peer Group of companies for the same period. Total shareholder return
represents stock price changes and assumes the reinvestment of dividends. The
graph assumes the investment of $100 on September 30, 1994.
9/30/94 9/30/95 9/30/96 9/30/97 9/30/98 9/30/99
------------ -------- ------- ------- ------- -------
UCI MEDICAL AFFILIATES, INC. $ 100.00 $ 103.09 $ 128.87 $ 103.09 $ 46.39 $ 23.20
NASDAQ MARKET INDEX (US) 100.00 121.41 141.75 192.67 200.23 323.92
PEER GROUP 100.00 223.67 412.75 330.38 156.58 75.13
The members of the Peer Group are AmeriPath, Inc., ContinuCare
Corporation, IntegraMed America, Inc., Pediatrix Medical Group, Inc., PhyCor,
Inc., and ProMedCo Management Company. The returns of each company in the Peer
Group have been weighted according to their respective stock market
capitalization for purposes of arriving at a Peer Group average. The September
30, 1994 and 1995 prices of the Company's Common Stock used in computing the
returns reflected above are the average of the high and low bid prices reported
for the Common Stock during the fiscal quarter ended on such dates.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information known to the Company
regarding the beneficial ownership of Common Stock as of December 31, 1999.
Information is presented for (i) stockholders owning more than five percent of
the outstanding Common Stock, (ii) each director and executive officer of the
Company, individually, and (iii) all directors and executive officers of the
Company, as a group. The percentages are calculated based on 9,650,515 shares of
Common Stock outstanding on December 31, 1999.
Shares
Name Percentage
Beneficially
Owned (1)
MainStreet Healthcare Corporation (2)...................................2,901,396 30.10%
Blue Cross Blue Shield of South Carolina (3)............................2,624,623 27.20
M.F. McFarland, III, M.D. (4).............................................681,294 6.95
Harold H. Adams, Jr.........................................................2,500 -0-
Thomas G. Faulds ............................................................-0- -0-
A. Wayne Johnson (5)....................................................2,901,396 30.10
Ashby M. Jordan, M.D..........................................................-0- -0-
John M. Little, Jr., M.D......................................................-0- -0-
Charles M. Potok. ............................................................-0- -0-
D. Michael Stout, M.D. (6) ...............................................330,576 3.40
Jerry F. Wells, Jr. (7) ..................................................106,550 1.09
All current directors and executive officers
as a group (9 persons)...............................................4,022,316 40.22
* Amount represents less than 1.0 percent.
(1) Beneficial ownership reflected in the table is determined in accordance
with the rules and regulations of the SEC and generally includes voting
or investment power with respect to securities. Shares of Common Stock
issuable upon the exercise of options currently exercisable or
convertible, or exercisable or convertible within 60 days, are deemed
outstanding for computing the percentage ownership of the person
holding such options, but are not deemed outstanding for computing the
percentage ownership of any other person. Except as otherwise
specified, each of the stockholders named in the table has indicated to
the Company that such stockholder has sole voting and investment power
with respect to all shares of Common Stock beneficially owned by that
stockholder.
(2) The business address of the named beneficial owner is 2370 Main Street,
Tucker, Georgia 30084.
(3) The business address of the named beneficial owner is
I-20 at Alpine Road, Columbia, SC 29219. The shares reflected in the table are
held of record by CHC (2,006,442 shares) and CP&C (618,181 shares), each of
which is a wholly-owned subsidiary of BCBS.
(4) The business address of the named beneficial owner is 1901 Main Street,
Suite 1200, Columbia, SC 29201. Shares reflected in the table include
159,450 shares issuable pursuant to currently exercisable stock
options.
(5) All shares reflected as beneficially owned are held of record by
MainStreet Healthcare Corporation. Mr. Johnson is Chairman, Chief Executive
Officer and a principal shareholder of MainStreet Healthcare Corporation.
(6) Includes 83,216 shares issuable pursuant to currently exercisable stock
options.
(7) All shares are issuable pursuant to currently exercisable stock options.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the 1934 Act requires the directors and officers of
the Company to file reports of holdings and acquisitions in Common Stock with
the Securities and Exchange Commission (the "SEC"). Based on the Company records
and other information, the Company believes that all SEC filing requirements
applicable to its directors and officers were complied with in respect to the
Company's fiscal year ended September 30, 1999.
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Administrative Services Agreements
UCI-SC has entered into an Administrative Services Agreement with
DC-SC. UCI-GA has entered into Administrative Services Agreements with each of
Doctor's Care of Georgia, P.C. and Doctor's Care of Tennessee, P.C.
(collectively, the UCI-PCs ). Under these Administrative Services Agreements,
UCI-SC and UCI-GA perform all non-medical management of DC-SC and the UCI-PCs
(collectively with DC-SC, the "PCs"), and have exclusive authority over all
aspects of the business of the PCs (other than those directly related to the
provision of patient medical services or as otherwise prohibited by state law).
The non-medical management provided by UCI-SC and UCI-GA includes, among other
functions, treasury and capital planning, financial reporting and accounting,
pricing decisions, patient acceptance policies, setting office hours,
contracting with third party payors and all administrative services. UCI-SC and
UCI-GA provide all of the resources (systems, procedures and staffing) to bill
third party payors or patients, and provide all of the resources (systems,
procedures and staffing) for cash collection and management of accounts
receivables, including custody of the lockbox where cash receipts are deposited.
From the cash receipts, UCI-SC and UCI-GA pay all physician salaries, operating
costs of the centers and operating costs of UCI-SC and UCI-GA. Compensation
guidelines for the licensed medical professionals at the PCs are set by UCI-SC
and UCI-GA, and UCI-SC and UCI-GA establish guidelines for establishing,
selecting, hiring and firing the licensed medical professionals. UCI-SC and
UCI-GA also negotiate and execute substantially all of the provider contracts
with third party payors, with the PCs executing certain of the contracts at the
request of a minority of payors. Neither UCI-SC nor UCI-GA loans or otherwise
advances funds to any PC for any purposes.
During the Company's fiscal years ended September 30, 1999 and 1998,
the PCs received an aggregate of approximately $40,470,000 and $37,566,000,
respectively, in fees prior to deduction by the PCs of their payroll and other
related deductible costs covered under the Administrative Agreement and its
predecessor agreement. For accounting purposes, the operations of the PCs are
combined with the operations of the Company and are reflected in the
consolidated financial statements of the Company. Pursuant to the employment
agreement between DC-SC and Dr. McFarland, Dr. McFarland serves as Executive
Medical Director of the Centers, and is paid an annual salary for his services
in such position. Footnote (3) of the Summary Compensation Table in this Proxy
Statement describes compensation paid to Dr. McFarland by DC-SC during the
fiscal years ended September 30, 1999, 1998 and 1997. Pursuant to the employment
agreement between DC-SC and Dr. Stout, Dr. Stout provides medical services to
DC-SC, and is paid an annual salary for such services. Footnote (4) of the
Summary Compensation Table in this Proxy Statement describes compensation paid
to Dr. Stout by DC-SC during the fiscal years ended September 30, 1999, 1998 and
1997. Dr. McFarland is the Chief Executive Officer of the Company and is the
President, sole director and sole owner of DC-SC. Dr. Stout is the Executive
Vice President of Medical Affairs for the Company, UCI-SC and UCI-GA, and is the
President, sole director and sole stockholder of the UCI-PCs.
Medical Center Leases
During the fiscal year ended September 30, 1999, UCI-SC leased six
medical center facilities from CHC and one medical center facility from CP&C. At
September 30, 1999, UCI-SC leased four medical center facilities from CHC and
one medical center facility from CP&C under operating leases with fifteen-year
terms expiring in 2008, 2009 and 2010. The terms of these leases are believed to
be no more or less favorable to UCI-SC than those that would have been
obtainable through arm's-length negotiations with unrelated third parties for
similar arrangements. Each of these leases has a five-year renewal option, and a
rent guarantee by DC-SC. One of the leases has a purchase option allowing UCI-SC
to purchase the center at fair market value after February 1, 1995. Total lease
payments made by UCI-SC under these leases during the fiscal years ended
September 30, 1999 and 1998 were $257,025 and $326,093, respectively.
The Doctor's Care Northeast facility is leased from a partnership in
which Dr. McFarland is a general partner. The lease was renewed in October 1997
for a fifteen-year term. The terms of this lease are believed to be no more or
less favorable to UCI-SC than those that would have been obtainable through
arm's-length negotiations with unrelated third parties for similar arrangements.
Total lease payments made by UCI-SC under this lease during the fiscal years
ended September 30, 1999 and 1998 were $96,000 and $62,400, respectively, plus
utilities and real estate taxes.
Beginning in August 1999, the Doctor's Care facility in Tucker, Georgia
was leased from A. Wayne Johnson. The terms of this lease are believed to be no
more or less favorable to UCI-SC than those that would have been obtainable
through arm's-length negotiations with unrelated third parties for similar
arrangements. The lease agreement expires in March 2008. Total lease payments
made by UCI-SC under this lease during the fiscal year ended September 30, 1999
were $7,200.
Other Transactions with Related Parties
At December 31, 1999, CHC owned 2,006,442 shares of Common Stock and
CP&C owned 618,181 shares of Common Stock, which combine to approximately 27.2
percent of the outstanding Common Stock. Each of CHC and CP&C is a wholly-owned
subsidiary of BCBS. The following is a historical summary of purchases of Common
Stock by BCBS subsidiaries directly from the Company.
Price Total
Date BCBS Number per Purchase
Purchased Subsidiary of Shares Share Price
12/10/93 CHC 333,333 $1.50 $ 500,000
06/08/94 CHC 333,333 3.00 1,000,000
01/16/95 CHC 470,588 2.13 1,000,000
05/24/95 CHC 117,647 2.13 250,000
11/03/95 CHC 218,180 2.75 599,995
12/15/95 CHC 218,180 2.75 599,995
03/01/96 CHC 109,091 2.75 300,000
06/04/96 CP&C 218,181 2.75 599,998
06/23/97 CP&C 400,000 1.50 600,000
The Common Stock acquired by CHC and CP&C directly from the Company was
purchased pursuant to exemptions from the registration requirements of federal
securities laws available under Section 4(2) of the 1933 Act. Consequently, the
ability of the holders to resell such shares in the public market is subject to
certain limitations and conditions. The shares acquired by CHC and CP&C were
purchased at share prices below market value at the respective dates of purchase
in part as a consequence of the lower issuance costs incurred by the Company in
the sale of these unregistered securities and in part as consequence of the
restricted nature of the shares. CHC and CP&C have the right to require
registration of the stock under certain circumstances as described in the
respective stock purchase agreements. BCBS and its subsidiaries have the option
to purchase as many shares as may be necessary for BCBS and its subsidiaries to
maintain ownership of 47 percent of the outstanding Common Stock in the event
that the Company issues additional stock to other parties (excluding shares
issued to employees or directors of the Company).
During the fiscal year ended September 30, 1994, UCI-SC entered into a
capital lease purchase agreement with BCBS for a new billing and accounts
receivable system, which includes computer equipment, for an aggregate purchase
price of $504,000. UCI-SC has the option to purchase the equipment at the end of
the lease term for $1. The lease obligation recorded at September 30, 1999 is
$1,053,687, which includes lease addenda. The terms of the lease purchase
agreement are believed to be no more or less favorable to UCI-SC than the terms
that would have been obtainable through arm's-length negotiations with unrelated
third parties for a similar billing and accounts receivable system, which
includes computer equipment.
During the fiscal year ended September 30, 1994, UCI-SC entered into an
agreement with CP&C pursuant to which UCI-SC, through DC-SC, acts as the primary
care provider for injured workers of firms carrying worker's compensation
insurance through CP&C. Additionally, during the fiscal year ended September 30,
1995, UCI-SC executed a $400,000 note payable to CP&C payable in monthly
installments of $4,546 (including 11 percent interest) from April 1, 1995 to
March 1, 2010, collateralized by certain accounts receivable. The terms of the
agreement with CP&C are believed to be no more or less favorable to UCI-SC than
those that would have been obtainable through arm's-length negotiations with
unrelated third parties for similar arrangements.
UCI-SC, through DC-SC, provides services to members of a health
maintenance organization operated by CHC who have selected DC-SC as their
primary care provider. The terms of the agreement with CHC are believed to be no
more or less favorable to UCI-SC than those that would have been obtainable
through arm's-length negotiations with unrelated third parties for similar
arrangements.
The employees of the Company and its subsidiaries are offered health,
life, and dental insurance coverage at group rates from BCBS and its
subsidiaries. The group rates offered to the employees of the Company and its
subsidiaries are believed to be no more or less favorable to the Company and its
subsidiaries than those that would have been obtainable through arm's-length
negotiations with unrelated third parties for similar services.
STOCKHOLDER PROPOSALS
Proposals of stockholders of the Company which are intended to be
presented by such stockholders at the next Annual Meeting of the Company
stockholders must be received by the Company on or before October 5, 2000 in
order to be considered for inclusion in such proxy statement and form of proxy.
ANNUAL REPORT
A copy of the Company's Annual Report on Form 10-K for the fiscal year
ended September 30, 1999, a copy of which has been filed with the Securities and
Exchange Commission, accompanies this Proxy Statement.
By order of the Board of Directors,
M. F. McFarland, III, M.D.
Chairman of the Board
Columbia, South Carolina .........
January 28, 2000
UCI MEDICAL AFFILIATES, INC.
PROXY SOLICITED BY THE BOARD OF DIRECTORS FOR THE ANNUAL MEETING OF
STOCKHOLDERS TO BE HELD ON THURSDAY, MARCH 23, 2000 AT THE ADAM'S MARK
HOTEL, 1200 HAMPTON STREET, COLUMBIA, SOUTH CAROLINA AT 10:00 A.M.
LOCAL TIME.
The undersigned hereby acknowledges receipt of the Notice of
Annual Meeting of Stockholders and Proxy Statement for the
above-referenced Annual Meeting and appoints each of Jerry F. Wells,
Jr. and S. Louise Parker as proxy and attorney-in-fact of the
undersigned, each with full power of substitution, to vote all of the
shares of common stock of UCI Medical Affiliates, Inc., a Delaware
corporation, held or owned by the undersigned or standing in the name
of the undersigned at the Annual Meeting of Stockholders of the Company
and at any adjournments thereof, and the undersigned hereby instructs
said proxies and attorneys to vote as follows:
1. Election of Directors:....Terms as set forth in Proxy Statement
FOR the nominee listed below ........................ WITHHOLD AUTHORITY
to vote as to the nominee
Harold H. Adams, Jr.......[ ] .............................. [ ]
Thomas G. Faulds..[ ] ............................. ...... [ ]
2. To ratify the appointment of PricewaterhouseCoopers LLP as the firm of
independent auditors for the Company for the fiscal year ended September 30,
2000.
FOR [ ]..........................AGAINST [ ]..............ABSTAIN [ ]
3. In the discretion of each proxy and attorney-in-fact, upon any other
business which may properly come before the meeting or any adjournment thereof.
DATE: ,
----------------------------------------------- 2000........
(Signature)*
NUMBER OF SHARES: .................
---------------------------
(Signatures, if held jointly)......
Print Name
(Please sign exactly as shown on the
envelope addressed to you.)
* Note: When shares are held by joint tenants, both should sign.
When signing as attorney, executor, administrator, trustee,
guardian or corporate officer or partner, please give full
title as such. If a corporation, please sign in corporate name
by president or other authorized officer. If a partnership,
please sign in partnership name by authorized person.
THIS PROXY WILL BE VOTED AS INSTRUCTED. IN THE ABSENCE OF SUCH
INSTRUCTIONS, THIS PROXY WILL BE VOTED "FOR" EACH OF THE PROPOSALS
LISTED, AND THE PROXIES HEREIN NAMED WILL VOTE ON OTHER MATTERS THAT
MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF IN
ACCORDANCE WITH THEIR JUDGMENT.